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COMMENTS 
Uncommon Genes, Unpatentable Subject Matter 
Adriane Scola† 
“More than twenty years of pure policy arguments [against patents 
on human gene sequences] have gotten nowhere in the courts, and 
Congress has shown no inclination to put the lucrative biotechnolo-
gy genie back into the bottle.”1 
I. INTRODUCTION 
In a landmark decision on March 29, 2010, Judge Sweet of the 
Southern District of New York ruled on the first case challenging patents 
granted by the United States Patent and Trademark Office (USPTO) for 
gene sequences.2 The plaintiffs3 challenged the validity of Myriad Genet-
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 1. John M. Conley & Roberte Makowski, Back to the Future: Rethinking the Product of Nature 
Doctrine as a Barrier to Biotechnology Patents (Part I), 85 J. PAT. & TRADEMARK OFF. SOC’Y 301, 
307–08 (2003). 
 2. Ass’n for Molecular Pathology v. USPTO, 702 F. Supp. 2d 181 (S.D.N.Y. 2010). 
 3. The plaintiffs include the Association for Molecular Pathology, the American College of 
Medical Genetics, the American Society for Clinical Pathology, the College of American Patholo-
gists, Dr. Haig Kazazian (University of Pennsylvania School of Medicine), Dr. Arupa Ganguly 
(University of Pennsylvania), Dr. Wendy Chung (Columbia University), Dr. Henry Ostrer (New 
York University School of Medicine), Dr. David Ledbetter (Emory University), Dr. Stephen Warren 
(Emory University), Ms. Ellen Matloff (Yale Cancer Genetic Counseling Program), Ms. Elsa Reich 
(Department of Pediatrics at New York University), Breast Cancer Action, Boston Women’s Health 
Book Collective, Ms. Lisbeth Ceriani (patient), Ms. Runi Limary (patient), Ms. Genae Girard (pa-
tient), Ms. Patrice Fortune (patient), Ms. Vicky Thomason (patient), and Ms. Kathleen Raker (pa-
tient). Id. at 186–89. 
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ics’4 patents on the BRCA1 and BRCA2 genes.5 Myriad holds exclusive 
licenses for the patents claiming both the BRCA gene sequences and the 
mutations associated with those sequences.6 These licenses grant Myriad 
the sole authority to test patients for BRCA mutations.7 Because muta-
tions in the BRCA genes correlate with a genetic predisposition to cer-
tain types of cancers,8 the plaintiffs alleged that the grant of exclusionary 
rights to Myriad for the BRCA gene sequences inhibited patient access to 
medically relevant diagnostic tests and unnecessarily increased the cost 
associated with such tests.9 Six different breast-cancer patients claimed 
they either received limited testing or could not afford tests due to My-
riad’s enforcement of its patent rights.10 In this case, Judge Sweet sided 
with the plaintiffs, holding that, as a matter of law, Myriad’s patents 
claiming the BRCA1/2 gene sequences are invalid.11 
The Myriad litigation is just one example of the ongoing debate 
over patents on DNA sequences. The Myriad decision is currently before 
the Federal Circuit and may make its way to the United States Supreme 
Court, giving the judiciary an opportunity to weigh and clarify a ques-
tionable USPTO policy. The debate has taken several forms involving 
legal, ethical, and public-policy concerns.12 Members of the biopharma-
ceutical industry argue that patents are necessary to promote new genetic 
technologies.13 In contrast, gene-patent opponents believe that human 
DNA patents are dubious patentable subject matter under both legal and 
ethical rationales.14 The USPTO grants gene-sequence patents on the 
grounds that the isolated and purified gene, extracted from the cell, con-
                                                 
 4. Plaintiffs asserted claims against the USPTO, Myriad Genetics, and the directors of the 
University of Utah Research Foundation. Id. at 189–90. 
 5. BRCA is the shorthand name for Breast Cancer Susceptibility Gene. BRCA1 refers to the 
first gene sequence identified that is associated with breast cancer. BRCA2 refers to the second gene 
identified. Id. at 201–03. 
 6. Id. 
 7. Id. 
 8. Id. at 203 (noting that women with BRCA1/2 mutations have an increased risk of developing 
breast cancer (up to 85% chance) and ovarian cancer (up to 50% chance)). 
 9. Id. at 204. Women who were unable to afford the full out-of-pocket cost for Myriad’s tests 
were denied testing because, although other laboratories were able to perform the tests at a much 
lower cost, Myriad’s patent rights barred those laboratories from offering similar tests. Id. 
 10. Id. at 188–89. 
 11. Id. at 232. 
 12. See generally SEC’Y’S ADVISORY COMM. ON GENOMICS, HEALTH & SOC’Y (SACGHS), 
REVISED DRAFT REPORT ON GENE PATENTS AND LICENSING PRACTICES AND THEIR IMPACT ON 
PATIENT ACCESS TO GENETIC TESTS (2010) [hereinafter SACGHS REPORT]. 
 13. E.g., Gregory C. Ellis, Emerging Biotechnologies Demand Defeat of Proposed Legislation 
that Attempts to Ban Gene Patents, 15 RICH. J.L. & TECH. 1, 1–3 (2008). 
 14. See generally Lori B. Andrews & Jordan Paradise, Gene Patents: The Need for Bioethics 
Scrutiny and Legal Change, 5 YALE J. HEALTH POL’Y L. & ETHICS 403 (2005). 
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stitutes something different from DNA as it is found in nature.15 Conse-
quently, if “isolated” DNA is never found in nature, it should be amena-
ble to patent protection. This construction is problematic, however, be-
cause there is no functional difference between a DNA sequence found 
in the cell and a DNA sequence isolated from the cell.16 Judge Robert H. 
Sweet, persuaded that the patents claimed genetic information as it is 
found in nature, interpreted the BRCA gene sequences as products of 
nature.17 Accordingly, he decided that gene sequences are a form of un-
patentable subject matter and held that Myriad’s gene patents were 
invalid.18 
Human gene sequences are not only products of nature, but also 
products of cultural heritage. Although the USPTO fails to effectively 
balance the competing business and human interests associated with 
DNA sequence patents, the international community tries to weigh these 
interests appropriately.19 To date, however, the ethics-based doctrine of 
Common Heritage has been largely ineffective in overriding competing 
business interests.20 The basic tenet of Common Heritage supposes that 
certain resources are part of the common heritage of humanity, and that 
communal property rights, rather than individual rights, are appropriate 
for such resources.21 Although the doctrine has been cited as an ethical 
bar to gene patents, as generally conceptualized, this application of the 
doctrine is suspect for at least two reasons. First, the idea of a common 
human genome is an abstraction; only identical twins share a common 
genome.22 Second, a common genome is not the subject of patent claims 
over gene sequences.23 
                                                 
 15. See Utility Examination Guidelines, 66 Fed. Reg. 1092 (Jan. 5, 2001) [hereinafter Utility 
Examination Guidelines], available at http://www.uspto.gov/web/offices/com/sol/og/2001/week05/ 
patutil.htm. 
 16. Unlike a situation where a researcher has altered the genetic composition of an organism to 
something that is not found in nature, a merely isolated gene sequence has not been altered to have a 
different function. The DNA sequence is the same whether it is contained within the cell or whether 
it exists in a test tube. 
 17. Ass’n for Molecular Pathology v. USPTO, 702 F. Supp. 2d 181, 232 (S.D.N.Y. 2010). 
 18. Id. 
 19. See Andrews & Paradise, supra note 14, at 403–04. 
 20. Pilar N. Ossorio, The Human Genome as Common Heritage: Common Sense or Legal 
Nonsense?, 35 J.L. MED. & ETHICS 425, 425–26 (2007). For a more general discussion of the oppo-
sition to gene patents, see Ellis, supra note 13. “[S]o-called moral opposition against gene pa-
tents . . . rarely amounts to any meaningful proposals of reform.” Id. at 8. 
 21. For example, the seabed is considered to be the property of all humanity. 
 22. See infra Part V. 
 23. See Ossorio, supra note 20, at 431 (noting that each individual’s genome is different from 
another individual’s and that gene-sequence patents only cover very short DNA regions contained 
within a particular genome). 
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This Comment argues that although human gene sequences do not 
reflect a common human heritage, such sequences do reflect human cul-
tural heritage. A patent that unfairly restricts access to basic genetic in-
formation generates wealth for the patent holder without regard to an 
individual’s right to basic knowledge—knowledge that can be characte-
rized and afforded legal protection as intangible cultural heritage. Much 
discussion is directed at the biological properties of DNA, but very little 
attention is given to the relationship between a human gene and its cul-
tural derivation. While it is true that patent claims encompass only indi-
vidual genes and gene fragments, these genetic regions and mutations 
result from human cultural and genetic evolution.24 Genetic mutations 
distinguish individuals by virtue of different family genealogies.25 Simi-
larly, genetic mutations differentiate groups of people that share a com-
mon cultural heritage.26 Any gene sequence is part of an individual’s 
family history and group affiliation. 
Human gene sequences can be conceptualized in three ways: as a 
molecular fragment, as genetic information, and as a product of cultural 
heritage.27 This Comment uses the BRCA litigation as an organizing 
principle to discuss the importance of understanding human genes as 
something more than just biological material.28 Part II addresses the 
background of the BRCA gene-patent case and the legal arguments 
against patenting gene sequences. Part III discusses the ethical objections 
to gene patents by focusing on common-heritage rationales. Further, Part 
III addresses the inadequacy of the Common Heritage Doctrine as ap-
plied to human gene sequences. Part IV highlights the international and 
domestic protections afforded to cultural heritage. Part V argues that be-
cause human genetic variation results from complex cultural and evolu-
tionary processes, gene sequences should be protected from appropria-
tion as intangible cultural heritage. Finally, Part VI offers some conclud-
ing thoughts. 
                                                 
 24. For a general discussion concerning the interplay between genetic forces, environmental 
impact, and cultural adaptation, see MARK A. JOBLING, MATTHEW HURLES & CHRIS TYLER-SMITH, 
HUMAN EVOLUTIONARY GENETICS: ORIGINS, PEOPLES & DISEASE 401–38 (Garland Science 2004). 
 25. See id.; see discussion infra Part V. 
 26. See JOBLING, HURLES & TYLER-SMITH, supra note 24, at 401–38. 
 27. See Debra Greenfield, Intangible or Embodied Information: The Non-Statutory Nature of 
Human Genetic Material, 25 SANTA CLARA COMPUTER & HIGH TECH. L.J. 467, 468–69 (2009) 
(discussing DNA as both a tangible molecule and intangible information). 
 28. As the focus of this Comment is conceptualizing genes as both biological and cultural 
products, it deals only with patents that directly claim a human gene or gene fragment. This Com-
ment does not address the efficacy of gene-related product or method patents, nor does it address 
gene patents claiming the genetic material of other species. 
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II. BACKGROUND 
A. Ass’n for Molecular Pathology v. USPTO 
On March 29, 2010, Judge Sweet granted the plaintiffs’ motion for 
summary judgment to declare invalid fifteen patent claims contained in 
seven of Myriad’s BRCA patents.29 The plaintiffs, represented by the 
American Civil Liberties Union (ACLU), included individuals from 
medical and advocacy organizations, as well as researchers, genetic 
counselors, and women either threatened by the risk of breast cancer or 
struggling to fight breast cancer.30 The plaintiffs claimed that patents 
granted for the BRCA1 and BRCA2 gene sequences were unlawful un-
der each of the following: (1) the Patent Act of 1952,31 (2) Article I, Sec-
tion 8, Clause 8, of the United States Constitution (the Patent and Copy-
right Clause), and (3) the First and Fourteenth Amendments of the Unit-
ed States Constitution.32 In granting the plaintiffs’ motion for summary 
judgment, Judge Sweet acknowledged the special significance of the 
claims before the court: “The resolution of the issues presented to this 
Court deeply concerns breast cancer patients, medical professionals, re-
searchers, caregivers, advocacy groups, existing gene patent holders and 
their investors, and those seeking to advance public health.”33 
At trial, defense attorney Brian Poissant characterized the ACLU’s 
position as an attack “on biotechnology patenting that warn[s] of the 
‘gruesome parade of horribles’ that will happen if companies are given 
patents over biological phenomena.”34 Furthermore, he noted that “if a 
ruling were as broadly applied here as the ACLU [contends] then it could 
‘undermine the entire biotechnology sector.’”35 Concerned, but not per-
suaded, Judge Sweet ruled for the plaintiffs, convinced that Myriad’s 
patents claimed DNA as it is found in nature.36 Judge Sweet concluded 
that natural products are “unsustainable as a matter of law and are 
deemed unpatentable subject matter under 35 U.S.C. § 101.”37 
Judge Sweet’s trepidations mirror the public’s concerns about the 
gene-patent debate.38 The plaintiffs’ legal challenges to the BRCA pa-
                                                 
 29. Ass’n for Molecular Pathology v. USPTO, 702 F. Supp. 2d 181, 184–85 (S.D.N.Y. 2010). 
 30. Id. at 186–89. 
 31. 35 U.S.C. § 101 (2006). 
 32. Molecular Pathology, 702 F. Supp. 2d at 184. 
 33. Id. at 185. 
 34. Matt Jones, Myriad, ACLU Clash over Gene IP in NY Court, GENOMEWEB DAILY NEWS 
(Feb. 2, 2010), http://www.genomeweb.com/dxpgx/myriad-aclu-clash-over-gene-ip-ny-court. 
 35. Id. 
 36. Molecular Pathology, 702 F. Supp. 2d at 185. 
 37. Id. 
 38. See Andrews & Paradise, supra note 14, at 403–04 (“Intense opposition to gene patents 
is . . . coming from researchers, politicians, organized religions, indigenous groups, patient groups, 
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tents raise a difficult legal and ethical dilemma: should information about 
an individual’s personal genetic identity be protectable as intellectual 
property for the purpose of promoting scientific innovation? On the one 
hand, resolving this thorny question in favor of the plaintiffs could affect 
the future of biomedical research.39 Conversely, a resolution favoring the 
defendants affects both personal healthcare and autonomy.40 
B. Why Do Gene-Sequence Patents Pass Muster Under the Patent Act? 
The United States Constitution defines Congress’s power “to pro-
mote the Progress of Science and useful arts, by securing for limited 
Times to Authors and Inventors the exclusive Right to their respective 
Writings and Discoveries.”41 The exclusionary rights granted by the 
Constitution are thought to create incentives for invention and stimulate 
the public dissemination of scientific innovation.42 Congress interprets 
exclusionary rights under the 1952 Patent Act (Patent Act) as encom-
passing “making, using, offering for sale, or selling the invention 
throughout the United States or importing the invention into the United 
States”43 for a current term of twenty years after the date of the patent 
application.44 The Patent Act codified statutory conditions under which 
the USPTO grants inventors patent protection for their inventions and 
discoveries.45 According to the Patent Act, four threshold requirements 
are necessary for the approval of patent protection: (1) patentable subject 
matter, (2) utility, (3) novelty, and (4) non-obviousness.46 
An invention is patentable subject matter under § 101 of the Patent 
Act when a person “invents or discovers any new and useful process, 
machine, manufacture, or composition, or any new and useful improve-
ment thereof . . . .”47 Congress interpreted the patentable subject matter 
requirement broadly, including “anything under the sun that is made by 
man.”48 Although almost any “thing” qualifies as § 101 subject matter, 
                                                                                                             
and medical professional organizations. Patents covering human genetic material raise a variety of 
issues . . . regarding privacy, autonomy, religious freedom, and reproductive liberty.”). 
 39. See Molecular Pathology, 702 F. Supp. 2d at 185. 
 40. Id. 
 41. U.S. CONST. art. I, § 8, cl. 8. 
 42. Diamond v. Chakrabarty, 447 U.S. 303, 308–09 (1980) (stating that the Patent Act was 
drafted in accordance with Thomas Jefferson’s philosophy that “ingenuity should receive a liberal 
encouragement”) (quoting 5 WRITINGS OF THOMAS JEFFERSON 75–76 (Washington ed. 1871)). 
 43. 35 U.S.C. § 154 (2006).  
 44. Id. 
 45. Id. §§ 101–103. 
 46. Id. This Comment is not concerned with the statutory requirements for novelty, utility, and 
non-obviousness. 
 47. Id. § 101. 
 48. Diamond v. Chakrabarty, 447 U.S. 303, 309 (1980) (citations omitted). 
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the “human-made” requirement is a sticking point; laws of nature, ab-
stract ideas, and natural phenomena fall outside the scope of patentable 
material.49 Because genetic material exists in cells, some commentators 
have identified gene sequences as unpatentable products or laws of na-
ture.50 In 1911, however, Judge Learned Hand distinguished molecules 
as they exist in nature from molecules that have been manipulated 
through processes like purification and isolation.51 Judge Hand articu-
lated the purification–isolation rationale in Parke-Davis & Co. v. H.K. 
Mulford Co.52 At issue in Parke-Davis was a patent for glandular adrena-
line that required the isolation of adrenaline from the body and subse-
quent laboratory purification.53 The court reasoned that although adrena-
line exists within the body in a natural form, the isolation and purifica-
tion of adrenaline from the gland was “for every practical purpose a new 
thing commercially and therapeutically.”54 Therefore, derivatives of nat-
ural products are appropriate patentable subject matter if they exhibit 
some new commercial property.55 
In 1980, the Supreme Court decided Diamond v. Chakrabarty and 
extended the purification rationale of Parke-Davis to biotechnological 
manipulation of naturally occurring organisms.56 In Diamond, the issue 
was whether a genetically modified bacterium qualified as a patentable 
                                                 
 49. Id. 
 50. See, e.g., Eileen M. Kane, Splitting the Gene: DNA Patents and the Genetic Code, 71 
TENN. L. REV. 707, 707 (2004). 
 51. Parke-Davis & Co. v. H.K. Mulford Co., 189 F. 95, 103 (C.C.S.D.N.Y. 1911). Although 
isolation and purification technically refer to two different processes (i.e., the physical separation of 
a molecule from its natural environment and then the removal of any associated substances to render 
a pure molecule), in the context of DNA, isolation and purification go hand in hand. DNA cannot be 
analyzed unless it is both separated from the body and the cell, as well as purified from biochemical 
compounds that inhibit further analysis. In this sense, DNA must necessarily be both separated and 
clean before a researcher can make any use of it. 
 52. Id. 
 53. Id. at 97. 
 54. Id. at 103. The court stated: 
Nor is the patent only for a degree of purity, and therefore not for a new “composition of 
matter.” As I have already shown, it does not include a salt, and no one had ever isolated 
a substance which was not in salt form, and which was anything like Takamine’s. Indeed, 
Sadtler supposes it to exist as a natural salt, and that the base was an original production 
of Takamine’s. That was a distinction not in degree, but in kind. But, even if it were 
merely an extracted product without change, there is no rule that such products are not 
patentable. Takamine was the first to make it available for any use by removing it from 
the other gland-tissue in which it was found, and, while it is of course possible logically 
to call this a purification of the principle, it became for every practical purpose a new 
thing commercially and therapeutically. That was a good ground for a patent. 
Id. 
 55. See id. 
 56. Diamond v. Chakrabarty, 447 U.S. 303, 313 (1980). 
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manufactured product.57 The Court held that “the patentee has produced 
a new bacterium with markedly different characteristics from any found 
in nature. . . . His discovery is not nature’s handiwork . . . under § 101.”58 
Although no court has extended the isolation and purification reasoning 
to DNA-sequence patents, the USPTO cites the above cases in support of 
issuing such patents on isolation and purification grounds.59 But the “iso-
lation and purification” of a DNA molecule does not change the informa-
tional content of the molecule.60 The processes used to isolate and purify 
DNA are laborious, but the end product in isolated form is not function-
ally different from the molecule found within the cell.61 The DNA prod-
uct contains the same nucleotide sequence as the in vivo molecule: the 
informational content that a researcher hopes to determine. While it is 
true that the isolated molecule is different because it has been stripped of 
the material that inhibits its analysis, it is the informational content of 
DNA that makes the sequence useful. Identifying the sequence of the 
                                                 
 57. Id. at 309. 
 58. Id. at 310. 
 59. See Utility Examination Guidelines, supra note 15. 
 Several comments state that while inventions are patentable, discoveries are not pa-
tentable. According to the comments, genes are discoveries rather than inventions. These 
comments urge the USPTO not to issue patents for genes on the ground that genes are not 
inventions. Response: The suggestion is not adopted. An inventor can patent a discovery 
when the patent application satisfies the statutory requirements. The U.S. Constitution 
uses the word “discoveries” where it authorizes Congress to promote progress made by 
inventors. The pertinent part of the Constitution is Article 1, section 8, clause 8, which 
reads: “The Congress shall have power * * * To promote the Progress of Science and 
useful Arts, by securing for limited Times to Authors and Inventors the exclusive Right 
to their respective Writings and Discoveries.” 
 When Congress enacted the patent statutes, it specifically authorized issuing a pa-
tent to a person who “invents or discovers” a new and useful composition of matter, 
among other things. The pertinent statute is 35 U.S.C. 101, which reads: “Whoever in-
vents or discovers any new and useful process, machine, manufacture, or composition of 
matter, or any new and useful improvement thereof, may obtain a patent therefore, sub-
ject to the conditions and requirements of this title.” Thus, an inventor’s discovery of a 
gene can be the basis for a patent on the genetic composition isolated from its natural 
state and processed through purifying steps that separate the gene from other molecules 
naturally associated with it. 
Id. 
 60. Greenfield, supra note 27, at 467, 478 (2009) (“Although scientists, social scientists, and 
historians since the early 1950s have described deoxyribonucleic acid (DNA) sequences as informa-
tion, this characterization has yet to be recognized by the law of intellectual property.”). 
 61. Id. at 478–79. 
A thorough examination of the types of sequences that are actually being claimed and the 
manner in which they are claimed fails to establish any meaningful distinctions under the 
law. Instead, it reveals only an abstraction, a construct: “Thus stripped of its identity as 
‘natural,’ the unencumbered gene becomes readily susceptible to the creation and layer-
ing upon it of a new legal identity as ‘man-made’ through scientific interventions.” 
Id. (quoting Jonathan Kahn, What’s the Use? Law and Authority in Patenting Human Genetic Ma-
terial, 14 STAN. L. & POL’Y REV. 417, 426 (2003)). 
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DNA fragment is the baseline step necessary before further useful disco-
veries can be achieved. Once this information is available, researchers 
can, for example, correlate the presence of mutations within the sequence 
with some particular outcome like increased risk of disease. A gene-
sequence patent claiming the baseline nucleotide sequence of isolated 
DNA, therefore, prevents others from using the sequence information to 
create different tests or diagnostic technologies. 
To illustrate, the challenged claims of BRCA patents cover four 
categories. First, the patents claim isolated, ancestral62 forms of the 
BRCA genes and fragments of the BRCA genes consisting of at least 
fifteen nucleotides.63 Second, they cover isolated forms of the BRCA 
genes that have mutations; the mutations may or may not be associated 
with an increased risk of cancer.64 Third, the patents claim a method of 
analyzing a person’s BRCA sequences to determine whether the se-
quences contain mutations.65 Last, the patents claim a method of compar-
ing a patient’s BRCA gene sequences to the normal BRCA sequences in 
order to determine whether a genetic predisposition to breast cancer ex-
ists.66 In other words, the patents exclude others from sequencing a pa-
tient’s BRCA1 or BRCA2 gene, comparing that sequence to the BRCA 
reference sequences, and determining whether a patient has a heightened 
cancer risk. 
III. WHY SHOULD GENE SEQUENCES BE INAPPROPRIATE 
PATENT SUBJECT MATTER? 
A. Gene-Sequence Patents Negatively Affect 
Genetic Research and Healthcare 
The plaintiffs in Molecular Pathology alleged that the BRCA pa-
tents effectually bar all other entities from providing genetic testing for 
the BRCA genes.67 Additionally, these patents bar researchers from con-
ducting further research of the BRCA genes.68 This potential chill on fur-
                                                 
 62. Ancestral, or wild-type, forms of a particular gene refer to the initial sequence state of the 
gene that existed at some point in the past. 
 63. See Ass’n for Molecular Pathology v. USPTO, 702 F. Supp. 2d 181, 212–13 (S.D.N.Y. 
2010). For ease of discussion, I have summarized the general content for some of Myriad’s chal-
lenged patent claims in its ‘282, ‘441, and ‘857 patents as described by Judge Sweet in Molecular 
Pathology. 
 64. See id. 
 65. See id. 
 66. See id. at 213–14. Note also that one patent claims a method for determining the efficacy of 
a potential cancer therapeutic. 
 67. See id. at 206. 
 68. Id. I am not suggesting that Myriad enforces its patents against basic researchers; in fact, 
Myriad made public statements to the contrary. Id. Although Myriad does not currently enforce its 
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ther research is important because while Myriad’s mutation detection 
tests covered many mutations associated with a heightened cancer risk, 
the tests did not cover all known mutations associated with that risk.69 
Myriad’s patents effectively block other researchers from designing a 
test that would include mutations or sequence arrangements for which 
Myriad does not test. A failure to test for known mutations that correlate 
with cancer predisposition undermines the efficacy of diagnostic tests. 
Myriad’s patents discourage, and if enforced, prohibit researchers from 
designing new tests based on new knowledge. 
Gene-patent advocates counter the above claims in several ways, 
arguing that gene patents should be retained because: (1) gene patents are 
necessary to create incentives for biotechnological innovation,70 and 
(2) empirical research has not demonstrated that gene patents chill fur-
ther research or that patents increase the cost of, or access to, diagnostic 
tests.71 Gene-patent advocates argue that patent protection is crucial to 
drive investment in areas such as biopharmaceutical innovation.72 For 
example, biologics are drugs that have been derived from a living organ-
ism or cell or by recombinant DNA technology.73 The research and de-
velopment costs associated with bringing biologic drug therapies to the 
market are enormously high.74 Given the significant investments neces-
sary to carry out research and development, manufacturers often require 
a guarantee that those investments are recoverable.75 The economic-
investment argument, however, fails to separate the economic incentive 
provided by the patent on the gene sequence from the total economic 
incentive offered for the diagnostic or technological innovation. 
                                                                                                             
patents against basic researchers, the patent claims are broad enough to allow Myriad to block basic 
research should it choose to do so. In Metastasizing Patent Claims on BRCA1, Kepler et al. per-
formed a bioinformatics analysis for claim 5 of Myriad’s U.S. Patent No. 5,747,282. Their results 
show that claim 5 extends the breadth of the ‘282 patent to portions of the genome beyond the 
BRCA1 gene itself. They estimate that the small nucleotide fragment identified in claim 5 is likely 
present at least once in every human gene. By the letter of the patent then, any genetic research using 
this particular nucleotide fragment would be infringing, irrespective of whether that research con-
cerned BRCA1. Thomas B. Kepler, Colin Crossman & Robert Cook-Deegan, Metastasizing Patent 
Claims on BRCA1, 95 GENOMICS 312, 312–14 (2010). 
 69. See Molecular Pathology, 702 F. Supp. 2d at 206. The opinion suggests that Myriad cur-
rently tests for all known sequence mutations. The plaintiffs contend there was a period of time 
when Myriad failed to test for large rearrangements in the BRCA genes, despite knowledge that such 
mutational events are related to cancer predisposition. Id. 
 70. Ellis, supra note 13, at 3. 
 71. Cf. SACGHS REPORT, supra note 12, at 32–41. 
 72. Ellis, supra note 13, at 46. 
 73. Id. at 51. 
 74. See id. at 52–53 (“The incentive required to research and develop a biologic drug is no less 
than it would be for a traditional pharmaceutical drug. In actuality it is more.”). 
 75. Id. at 54. 
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There is little clarity as to which is more valuable: the patent on the 
underlying gene sequence or a patent on the innovative use of that gene 
sequence. The biotechnological innovation likely entails a novel use, 
modification, or application of the underlying sequence.76 On the one 
hand, if the value of the patented innovation is derived mainly from an 
innovative use, modification, or application, then claiming the underly-
ing sequence does not add much value. Thus, if the patent on the under-
lying sequence offers little actual value to the patent holder, then the 
economic-incentive argument fails because the sequence patent is super-
fluous. Alternatively, if the value of the patent derives mainly from 
blocking other researchers from developing other innovative uses, mod-
ifications, or applications of the underlying gene sequence, then the pa-
tent is contrary to the policy for granting patents.77 Under this scenario, 
the patent is valuable not because it provides an incentive to innovate, 
but because it prevents others from innovating. 
In response to the concerns about the chilling effect of gene patents 
and a lack of empirical evidence demonstrating such an effect, the U.S. 
Secretary’s Advisory Committee on Genetics, Health, and Society 
(SACGHS) conducted its own report to assess the validity of the asser-
tion that gene-sequence patents actually block other researchers from 
innovating.78 SACGHS commissioned the Revised Draft Report on Gene 
Patents and Licensing Practices and Their Impact on Patient Access to 
Genetic Tests (Report) to evaluate the potential blocking function of se-
quence patents and problems associated with patient access to genetic 
testing.79 The Report includes multiple empirical studies suggesting that 
a chilling effect on research currently exists.80 The fear of patent holders 
enforcing exclusionary rights for patents granted on foundational re-
search discoveries is a real concern for researchers.81 
Molecular Pathology demonstrates how this fear impacts health-
care. Myriad asserted its exclusionary rights over other clinicians and 
                                                 
 76. The discovery of a particular gene sequence is not innovative. See Matthew Erramouspe, 
Comment, Staking Patent Claims on the Human Blueprint: Rewards and Rent-Dissipating Races, 43 
UCLA L. REV. 961, 997 (1996). 
 77. Diamond v. Chakrabarty, 447 U.S. 303, 308–09 (1980). 
 78. SACGHS REPORT, supra note 12. 
 79. Id. SACGHS was chartered in 2002 by the Secretary of the U.S. Department of Health and 
Human Services as a forum for discussing the policy issues associated with issues surrounding ge-
netic testing. The Committee consists of seventeen individuals with specific expertise in the follow-
ing disciplines: biomedical sciences, human genetics, healthcare delivery, evidence-based practice, 
public health, behavioral sciences, social sciences, health services research, health policy, health 
disparities, ethics, economics, law, healthcare financing, and consumer issues. Id. at 1. 
 80. Id. at 83. 
 81. See id. 
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laboratories, limiting patient access to testing and testing validation.82 
The plaintiffs include six women, between the ages of thirty-two and 
fifty-two, who were adversely affected by Myriad’s exclusive right to 
provide BRCA1/2 diagnostic testing.83 These women were denied access 
to information about their own predisposition to aggressive cancers be-
cause the BRCA gene patent claims excluded other clinicians from per-
forming additional tests or the same tests at lower cost, or confirming 
Myriad’s test results.84 Women were denied access to the full range of 
preemptive options that could have prevented the cancer from develop-
ing or spreading.85 Myriad’s enforcement of its BRCA patents negatively 
affected these patients. 
Aside from the concerns about the clinical and research-blocking 
function of gene-sequence patents, some are disturbed by the appropria-
tion and commoditization of DNA.86 Although issuance of a patent does 
not confer property rights, the downstream effect is that patents generate 
wealth for patent holders.87 When considering human genes, the concern 
is that patents allow individuals and organizations to make money from 
genetic information that is both personal and communal.88 The debate 
rages on as to whether patent rights sufficiently balance the need to en-
courage genetic innovation against a perceived misappropriation of 
access to genetic knowledge.89 
Unfortunately, there has been no satisfactory theory levied in which 
to ground the fears about gene patents. Although strong ethics-based ar-
guments against DNA-sequence patents could bolster the cause for an 
                                                 
 82. Ass’n for Molecular Pathology v. USPTO, 702 F. Supp. 2d 181, 206 (S.D.N.Y. 2010). 
 83. Id. 
 84. Women may choose to have preemptive surgeries such as mastectomies after finding out 
the likelihood of developing breast cancer. If a woman does not have access to her personal risk 
assessment, she cannot make preemptive decisions. 
 85. Molecular Pathology, 702 F. Supp. 2d at 206. 
 86. See Ossorio, supra note 20, at 425 (“Many people can accept the plausibility of claims that 
all human beings have a profound interest in the human genome—that all people have a significant 
stake in how and whether the human genome is manipulated, and in what principles would guide its 
commercial exploitation.”). 
 87. Christopher M. Holman, The Impact of Human Gene Patents on Innovation and Access: A 
Survey of Human Gene Patent Litigation, 76 UMKC L. REV. 295, 302 (2007) (noting that there is 
often confusion as to the actual scope of rights associated with a patent grant: patent holders do not 
own genes; they merely own exclusionary rights against others wishing to use, make, or sell the 
inventions claimed in the patent application). There is an undoubtedly complicated relationship 
between the perceived strength of a company’s IP portfolio and its market value. While this Com-
ment does not attempt to discuss this phenomenon, it is interesting to note that Myriad’s stocks 
dropped roughly 7% the day following the Molecular Pathology decision. Anand Basu, Myriad 
Genetics Shares Fall After Court Denies Patents, REUTERS (Mar. 30, 2010, 11:05 AM), 
http://www.reuters.com/article/idUSTRE62T35X20100330. 
 88. Ossorio, supra note 20, at 431. 
 89. Molecular Pathology, 702 F. Supp. at 185. 
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immediate change in subject-matter classification, no such ethical viola-
tion has been clearly identified.90 While not prominent in U.S. policy 
discussions, the international community endorses the Common Heritage 
Doctrine to designate the human genome as the public property of all 
humanity.91 This Doctrine was publicly adopted by the United Nations, 
the international Human Genome Organization (HUGO), and the Coun-
cil of Europe.92 While enticing at least in the abstract, the Doctrine fits 
uncomfortably as an ethical rationale for exempting gene sequences from 
patentable subject matter. Classifying the human genome as common 
heritage oversimplifies the reality of human genetic variation. Further-
more, when drawn to its legal end, the Common Heritage Doctrine has 
unsatisfactory property-based consequences.93 
B. The Common Heritage Doctrine 
In The Human Genome as Common Heritage: Common Sense or 
Legal Nonsense, Pilar Ossorio reflects on the theoretical foundations of 
the Common Heritage Doctrine and discusses its applicability to the hu-
man genome.94 She notes that the Doctrine embodies two rationales for 
protecting certain objects or resources as the public property of all hu-
manity: (1) the Common Heritage Property Doctrine (CHPD) and (2) the 
Common Heritage Duties Doctrine (CHDD).95 The following discussion 
about common heritage reflects Ossorio’s research and insights about the 
two doctrinal forms. CHPD is the traditionally invoked doctrine to sup-
port ethical objections to DNA sequence patents.96 Because “CHPD vests 
all people or all nations with equal property interests in a territory or re-
source,” CHPD suggests that all people have a property interest in the 
human genome. 97 In contrast, CHDD recognizes individual property in-
terests in a common resource.98 CHDD imposes a duty to protect com-
mon resources from exploitation.99 Thus, under CHDD, individuals have 
personal property interests in the human genome and those collective 
interests warrant a duty to protect the genome from exploitation.100 While 
the application of CHPD to genetic information is problematic, CHDD 
                                                 
 90. See Ossorio, supra note 20, at 429. 
 91. Id. at 425. 
 92. Id. 
 93. Id. 
 94. Id. at 425–26. 
 95. Id. at 427. 
 96. Id. at 428–29. 
 97. Id. at 427, 429. 
 98. Id. at 430. 
 99. Id. 
 100. See id. 
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offers a compatible theoretical basis for protecting gene sequences as 
intangible cultural heritage.101 
CHPD was developed during the 1960s in response to concerns 
about disparate global power structure.102 Representatives of less indu-
strialized nations noted that benefits derived from resource exploitation 
become inequitably allocated.103 Because wealthy nations benefit unfair-
ly from resource exploitation, legal agreements between nations should 
be structured to account for benefit misallocation.104 By incorporating 
redistributive measures such as taxes and transfer agreements into re-
source-exploitation agreements, the benefits would be more evenly dis-
tributed.105 “Because of its particular history, the CHPD emphasized the 
distribution of benefits rather than the distribution of burdens or duties 
that might be associated with maintaining a [common heritage] re-
source.”106 In other words, CHPD recognizes that because of the global 
power structure, less powerful nations do not receive the benefits they 
are entitled to when common resources are exploited.107 
Given the benefit-driven nature of CHPD-designated resources, 
conceptualization of the human genome as a CHPD resource suggests 
that DNA could be commercially exploited so long as the benefits of 
commercial exploitation are equitably distributed.108 If a concern exists 
about whether gene sequences should be commoditized, then a theory 
that allows for exploitation of a common resource would be inconsistent 
with such an anti-gene-patent position. Notably, “[n]o codification of the 
CHPD prevents economic exploitation of the CH resources.”109 All the 
CHPD designation offers is the equitable distribution of benefits derived 
from commercial exploitation; it does not address whether commercial 
exploitation is an appropriate use of the resource.110 
Alternatively, CHDD developed out of international concern for the 
protection of cultural and national heritage. The nationalist-
preservationist development in Europe and England spurred this con-
cern.111 The CHDD language reflected this preservationist spirit and was 
codified in the Convention for the Protection of Cultural Property in the 
Event of Armed Conflict and the Convention for the Protection of the 
                                                 
 101. See id. at 431. 
 102. Id. at 427–28. 
 103. Id. 
 104. Id. 
 105. Id. at 428. 
 106. Id. 
 107. Id. 
 108. Id. at 429. 
 109. Id. 
 110. Id. 
 111. Id. at 430. 
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World Cultural and Natural Heritage.112 CHDD “reflects the rare situa-
tion in which a public resource is composed of incremental, individual 
holdings.”113 Resources such as cultural artifacts and natural wonders, 
though created or situated within a particular nation, should be protected 
from exploitation or degradation because they contribute to global cul-
ture.114 “[T]he doctrine reflects the normative stance that interdepen-
dence—among human beings and between humans and the non-human 
natural world—ought to be recognized and nurtured in national and in-
ternational policy.”115 Unlike the ideals of CHPD, the ideals of CHDD 
square satisfactorily with the protection of human gene sequences.116 
CHDD functions to protect and preserve important cultural resources.117 
It functions to allow private entities to hold cultural resources for the 
purpose of preserving them for future generations.118 
Although CHDD is an underdeveloped doctrine, it incorporates the 
ideals underlying protective regimes for items of cultural heritage.119 As 
argued below, gene sequences can be conceptualized as products of in-
tangible cultural heritage, and CHDD offers a duty-based, as opposed to 
property-based, rationale for protecting genetic information. The use of 
this doctrine is still problematic, however, because it labels the human 
genome as a common resource in need of preservation.120 As argued be-
low, the designation of the human genome as a common-heritage re-
source is inappropriate because individual genes embody an uncommon 
heritage. 
C. The Uncommon Heritage of Human Genes 
Although attention is often directed at the molecular-biological 
structure and content of DNA sequences, little attention is given to the 
human cultural and evolutionary history of genetic-sequence informa-
tion.121 If CHPD is applied to gene-sequence patents, the rationale can be 
                                                 
 112. Id. 
 113. Id. 
 114. Id. at 430–31. 
 115. Id. at 431. 
 116. See id. 
 117. Id. at 430. 
 118. Id. at 431. 
 119. See id. 
 120. See id. at 432. 
 121. Greenfield, supra note 27, at 471–72. 
Joining the social scientists and philosophers, scientists, engineers, biomedical research-
ers, and policy-makers have come to recognize that claims to DNA sequences can be per-
ceived and characterized as intangible information, separate and thus distinguishable 
from the tangible molecule in which it is contained. DNA sequences can also be de-
scribed or characterized as information which has materialized or is embodied as a mole-
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attacked on the following grounds: (1) there is no one human genome 
common to all humanity; (2) gene patents protect limited regions, genes, 
or mutations that are only a small piece of genetic material common to 
any one human genome; and (3) human populations exhibit large 
amounts of genetic variation both within and among groups.122 These 
attacks are difficult to overcome if the stated reason for sequence protec-
tion derives from an oversimplification of the meaning of genetic infor-
mation. The conceptualization of gene sequences as part of a united 
whole, whether literally or symbolically, provides little incentive to 
change an accepted intellectual property regime. 
1. There Is No One Human Genome 
In 2001, the Human Genome Project provided researchers access to 
a complete sequence of the entire human genome.123 Project contributors 
compiled a draft sequence patching together sequence data for every hu-
man gene.124 The complete sequence of the human genome⎯a spectacu-
lar accomplishment⎯gives researchers access to a resource for under-
standing human genetic evolution.125 The term “genome” refers to the 
entire amount of genetic information contained within our cells, includ-
ing nuclear DNA and cytoplasmic mitochondrial DNA.126 Nuclear DNA 
is diploid, meaning that we inherit one copy from each of our parents; 
thus, we each have two nuclear genomes that can be distinguished on the 
basis of genetic variation.127 Additionally, each of those genomes con-
tains unique mutations and variations that are different from all other 
individuals. The human genome discloses the identity of human genes as 
differentiated from those of other species; it is only common to all hu-
mans in that sense. In other words, the human genome is different than 
either the mouse genome or the dog genome, but the gene sequences 
found in my genome do not match those found in any other person’s ge-
                                                                                                             
cular structure. Simply, when considering the nature and character of human DNA, “the 
medium is . . . the message.” Despite this recognition and the growing literature devoted 
to the implications of human genetic material as information, intellectual property law to 
date has not treated it as such, but continues to allow the privatization of human genetic 
material in the form of patents based upon a limited and archaic definitional understand-
ing of DNA sequences as simply biological “wet” material. 
Id. 
 122. See David B. Resnik, The Human Genome: Common Resource but Not Common Herit-
age, in ETHICS FOR LIFE SCIENTISTS 195, 200–01 (Michiel Korthals & Robert J. Bogers eds., 2005). 
 123. See J. Craig Venter et al., The Sequence of the Human Genome, 291 SCIENCE 1304, 1304–
51 (2001), available at http://www.sciencemag.org/content/291/5507/1304.full. 
 124. Id. 
 125. JOBLING, HURLES & TYLER-SMITH, supra note 24, at 25. 
 126. The mitochondrial genome is a haploid molecule inherited only through the maternal line. 
 127. JOBLING, HURLES & TYLER-SMITH, supra note 24, at 25. 
2011] Uncommon Genes, Unpatentable Subject Matter 925 
nome sequence. Although it may seem obvious, the human genome is 
“common” only as an abstraction, not a literal entity. 
2. What Do Gene Patents Protect? 
Often, gene-patent claims encompass only a small portion of human 
genetic information.128 As noted above, the BRCA patents claim the gene 
sequences that code for BRCA proteins and small nucleotide fragments 
of those sequences.129 Importantly, gene-patent claims often extend not 
only to one identified sequence, but also to various mutations that may 
affect gene or protein function.130 Sometimes claims also extend to un-
discovered mutations.131 To return to the BRCA example, mutations 
found within the BRCA sequence are associated with predispositions to 
breast and ovarian cancers.132 Diagnostic tests like those used in BRCA-
variant identification rely on the presence or absence of certain mutations 
to predict disease predisposition.133 For these patents, the identification 
of the sequence mutations makes the BRCA patents valuable. Because 
mutations, by definition, reflect points of differentiation between indi-
viduals,134 it is inappropriate to assume that human commonality is a via-
ble rationale for eliminating patent protection for gene sequences. 
IV. INTERNATIONAL AND DOMESTIC PROTECTIONS 
FOR CULTURAL HERITAGE 
As noted in Part III.B, CHPD does not address concerns about ge-
netic appropriation. Because it fails to account for the economic exploita-
tion of public resources, CHPD will not allay fears about human genetic 
commercialization.135 But a cultural-heritage theory, consistent with the 
                                                 
 128. See, e.g., U.S. Patent No. 5,747,282 col.154 ll.56-58 (filed June 7, 1995). 
 129. Ass’n for Molecular Pathology v. USPTO, 702 F. Supp. 2d 181, 212–13 (S.D.N.Y. 2010). 
Additionally, the term “gene patent” has been used to refer to numerous types of claims, including 
divergent products and processes. See Holman, supra note 87, at 312. 
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of a naturally occurring protein. 
Id. 
 130. Molecular Pathology, 702 F. Supp. 2d at 212–13 (“Claim 6 of the ‘492 patent, however, 
is considerably broader than claim 1 and is directed to any DNA nucleotide encoding any mutant 
BRCA2 protein that is associated with a predisposition to breast cancer.”). 
 131. See id. 
 132. Id. at 185. 
 133. Id. 
 134. JOBLING, HURLES & TYLER-SMITH, supra note 24, at 46–86. 
 135. Ossorio, supra note 20, at 430. 
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ideals of CHDD, can allow for the protection of genetic resources. The 
international community created several legal regimes to protect cultural 
heritage from appropriation and commercial exploitation.136 Additional-
ly, although U.S. law centers mostly on property-based protections for 
tangible cultural artifacts, some legal precedent exists in U.S. federal In-
dian law to afford protection for intangible cultural heritage. 
Inevitably, a discussion about cultural heritage requires an attempt 
to define the term “culture.” Culture is enormously complex and anthro-
pologists have vigorously debated a satisfactory definition for over a cen-
tury.137 Despite its elusive definition, most people have a general sense of 
what culture encompasses. Culture might be defined as including all as-
pects of a group of people’s past, present, and future. It is the tangible 
art, writings, and architecture made by a particular group, but it is also 
the intangible knowledge, traditions, and beliefs held by that group.138 
Cultural heritage, then, is both the tangible and intangible culture passed 
down from generation to generation.139 
A. The International Community Recognizes and 
Protects Intangible Cultural Heritage 
The international community recognizes the importance of offering 
legal protections for both tangible and intangible cultural heritage.140 The 
2003 United Nations Educational, Scientific, and Cultural Organization 
(UNESCO) Convention on the Safeguarding of Intangible Cultural Her-
itage141 (2003 UNESCO Convention) seeks to protect intangible cultural 
heritage, ensure respect and appreciation of culturally derived materials, 
increase global awareness of its importance, and facilitate international 
cooperation and assistance.142 The 2003 UNESCO Convention was 
enacted in 2006 and features more than 100 state parties.143 It covers 
“practices, representations, expressions, knowledge, skills—as well as 
                                                 
 136. See discussion infra Part IV.A. 
 137. See Peter K. Yu, Cultural Relics, Intellectual Property, and Intangible Heritage, 81 TEMP. 
L. REV. 433, 441 (2008). 
 138. See id. at 443. 
 139. See id. (“Although the protection for cultural heritage initially focused primarily on [tang-
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 140. See id. 
 141. UNESCO Convention for the Safeguarding of the Intangible Cultural Heritage art. 1, Oct. 
17, 2003, 2368 U.N.T.S. 35 [hereinafter 2003 UNESCO Convention], available at 
http://unesdoc.unesco.org/images/0013/001325/132540e.pdf. 
 142. Yu, supra note 137, at 434. 
 143. Id. 
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the instruments, objects, [artifacts,] and cultural spaces associated there-
with . . . .”144 
In 2005, many signatories of the 2003 UNESCO Convention 
adopted the Convention on the Protection and Promotion of the Diversity 
of Cultural Expressions (2005 UNESCO Convention).145 The 2005 
UNESCO Convention aims to create beneficial conditions wherein cul-
tures can flourish independently and interact freely with other cultures.146 
Moreover, it encourages cultures and countries to engage in an ongoing 
dialogue.147 Additionally, in 2007, the United Nations adopted the Decla-
ration on the Rights of Indigenous Peoples (DRIPS).148 DRIPS articulates 
specific protectable rights of indigenous groups.149 Under DRIPS, those 
groups have “the right to maintain, control, protect and develop their cul-
tural heritage, traditional knowledge and traditional cultural expressions, 
as well as manifestations of their sciences . . . including human and ge-
netic resources.”150 In codifying the above conventions and declaration, 
the international community demonstrated its concern for protecting cul-
tural heritage from misappropriation. 
B. Limited Domestic Protection Exists for Cultural Heritage 
Protection of cultural heritage in the United States developed out of 
concern for protecting Native resources from commercial exploitation.151 
Currently, most legislation focuses on protecting tangible cultural re-
sources,152 but the Native American Graves Repatriation Act of 1990 
(NAGPRA)153 affords legal protection to both “sacred objects” and “cul-
tural patrimony.”154 Unlike earlier legislation that dealt with policing illi-
cit trade of art and cultural products,155 NAGPRA was passed with the 
                                                 
 144. 2003 UNESCO Convention, supra note 141, at art. 2, para. 1. 
 145. UNESCO Convention on the Protection and Promotion of the Diversity of Cultural Ex-
pressions, Oct. 20, 2005, 45 I.L.M. 269, available at http://unesdoc.unesco.org/ 
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 151. Stephen D. Osborne, Protecting Tribal Stories: The Perils of Propertization, 28 AM. 
INDIAN L. REV. 203, 218 (2003). 
 152. See id. 
 153. Native American Graves Protection and Repatriation Act, 25 U.S.C. §§ 3001–3013 
(2006). 
 154. Osborne, supra note 151, at 220. 
 155. Id. at 217. The Antiquities Act of 1906 established criminal penalties for individuals that 
destroyed or stole antiquities from federal land. Because the Antiquities Act was rarely enforced, 
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express purpose of recognizing tribal rights to Native American remains 
and associated artifacts.156 NAGPRA requires federally funded institu-
tions to inventory collections of human remains and funerary objects to 
determine cultural affiliation.157 If such remains are affiliated with a fed-
erally recognized tribal entity, the institution must repatriate the remains 
and objects.158 NAGPRA recognizes that Native American property 
rights exist in objects of cultural heritage and that these rights are in-
alienable.159 In identifying a category of items as “cultural patrimony,” 
NAGPRA acknowledges a communal interest in cultural resources.160 
Although U.S. law is generally concerned with affording individu-
al-based property protections, NAGPRA highlights at least the possibili-
ty that U.S. law can accommodate community-based rights for cultural 
heritage.161 
V. HUMAN GENE SEQUENCES ARE INTANGIBLE CULTURAL HERITAGE 
Humans do not comprise a single randomly mating population; 
there are patterns of genetic variation—or structure—that reflect a histo-
ry of geographical, linguistic, ethnic, cultural, and religious nonrandom 
assortment.162 Because these differences in experience helped to shape 
differences within our genes, gene sequences should be recognized as a 
form of intangible cultural heritage. 
Population genetics and anthropological genetics are disciplines 
that seek to understand how our genes reflect differences across popula-
tions and how evolutionary, environmental, and cultural processes have 
created that diversity within the human genome.163 By analyzing genetic 
                                                                                                             
Congress enacted the Archaeological Resources Protection Act (ARPA) of 1979. Similar to the 
Antiquities Act, ARPA punished looting and desecration of culturally valuable sites and artifacts. 
Neither Act, however, explicitly recognized the communal cultural rights of Native American 
groups. Id. at 216–17. 
 156. Id. at 218. 
 157. Id. 
 158. Id. at 219. 
 159. Id. Under NAGPRA, “cultural patrimony” is: 
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tive American group or culture itself, rather than property owned by an individual Native 
American, and which, therefore, cannot be alienated, appropriated, or conveyed by any 
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25 U.S.C. § 3001(3)(D) (2006). 
 160. Osborne, supra note 151, at 219. 
 161. See id. at 228. 
 162. See generally JOBLING, HURLES & TYLER-SMITH, supra note 24. 
 163. See id. 
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diversity between human populations, researchers tell a story about hu-
man history and cultural heritage.164 
A. Genes as Storytellers 
Although the causal relationships and interactions between cultural 
and genetic evolution are quite complicated, consider one illustration of a 
cultural–genetic coevolutionary relationship involving human adaptation 
to dietary change. Lactase persistence is the ability of an adult to digest 
lactose, the primary sugar found in milk.165 Although some adults are 
able to digest lactose beyond weaning, most adults lose that ability due to 
a rapid postweaning decrease in production of intestinal lactase, the en-
zyme that breaks down lactose.166 The effects of accumulated lactose in 
the intestine are associated with what we commonly refer to as lactose 
intolerance.167 The permanent reduction in lactase production after wean-
ing is common to all mammals and was the ancestral state of all humans 
until about ten thousand years ago.168 Currently, however, large numbers 
of people across the world retain the ability to produce lactase as 
adults.169 
The worldwide distribution of lactase persistence is highly nonuni-
form; the highest prevalence rates occur in European and African pasto-
ralist groups, while lower rates are found in the Middle East, the Medi-
terranean, and in south and central Asia.170 The lowest persistence rates 
are found among Native Americans, Pacific Islanders, and in people of 
sub-Saharan Africa and southeast Asia.171 The phenotype of lactase per-
sistence correlates with cultures that have historically used fresh milk, 
and it has long been thought to be associated with human adaptation to 
dietary change spurred by the advent of agriculture in the Middle East.172 
                                                 
 164. See id. 
 165. Dallas M. Swallow, Genetics of Lactase Persistence and Lactose Intolerance, 37 ANN. 
REV. GENETICS 197, 198 (2003). 
 166. JOBLING, HURLES & TYLER-SMITH, supra note 24, at 414. 
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 168. See Edward Hollox, Genetics of Lactase Persistence—Fresh Lessons in the History of 
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at 267–69. 
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Several hypotheses attempt to explain the geographic distribution of 
lactase persistence.173 One theory posits that if groups displayed strong 
cultural transmission of milk consumption from generation to generation, 
selective pressures following the adoption of dairying would account for 
the rapid spread of the persistence trait.174 The linear cultural transmis-
sion (strong reliance on milk consumption as opposed to other types of 
dietary consumption) would account for the population-specific distribu-
tion of the lactase-persistence trait.175 This example illustrates the lineage 
and culturally specific structuring of genetic diversity across human pop-
ulations. 
The lactase-persistence mutation is an example of a genetic muta-
tion directly correlated with a change in human behavior, but all genes 
are influenced by choices people make and reactions to cultural or envi-
ronmental stress.176 Genetic heritage is deeply intertwined with cultural 
heritage, and BRCA mutations, like all other genetic mutations, reflect 
unique historical events common to a particular group of people.177 
BRCA1 was the first gene discovered to be associated with heredi-
tary breast cancer.178 Although first named by Mary-Claire King’s re-
search team in 1991, Mark Skolnick and colleagues at Myriad Genetics 
successfully cloned BRCA1 in 1994 and BRCA2 in 1995.179 The Skol-
nick team identified truncation mutations180 within the coding regions181 
of the BRCA genes; many of these mutations introduce a stop codon182 
within the reading frame such that the mutated BRCA sequence produces 
a nonfunctional BRCA protein.183 Cells containing defective BRCA pro-
teins experience damage to double-stranded DNA.184 Because BRCA 
proteins are involved in DNA repair, damaged DNA is repaired via an 
error-prone process that results in chromosomal rearrangements.185 The 
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resulting chromosomal instability is thought to be a crucial feature of 
carcinogenesis.186 Although BRCA mutations were primarily studied for 
their association with aggressive forms of cancer, researchers continued 
to explore the historical and evolutionary significance of BRCA va-
riants.187 
Soon after the identification of the BRCA genes, researchers identi-
fied different BRCA mutations across several human populations, in-
cluding those in Finland, France, Hungary, Israel, Russia, and the United 
States.188 Similar to the lactase-persistence mutation, population-specific 
BRCA variants originated at different times and in different parts of the 
world; these variants were passed down within families and migrated to 
new places with their human carriers.189 Research shows that many 
BRCA mutations are “identical by descent,”190 meaning that mutations 
found in different individuals derive from a common ancestor, not by 
mere coincidence.191 If a mutation is identical by descent, one can extra-
polate the date when the mutation arose; thus, in locating the mutation in 
one geographic area at one particular point in time, it is possible to learn 
which individuals are more likely to be affected and to design back-
ground-specific screening methods to detect predispositions to breast and 
ovarian cancers.192 
For example, in 2008, F. Marroni and colleagues estimated the age 
of a BRCA1 mutation thought to be a founder allele—or first mutation of 
the ancestral state—originating in Tuscany.193 They reconstructed the 
genetic history of the mutation from carrier families and determined that 
the most recent common ancestor likely lived in Tuscany roughly 750 
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years ago.194 Individuals carrying the founder mutation dispersed 
throughout Italy sometime after that date.195 Given the estimated date, the 
dispersion of carrier individuals in Italy could have coincided with Lo-
renzo de’ Medici’s death in 1492.196 Following his death, the preacher 
Girolamo Savonarola prophesized the Apocalypse and persecuted ma-
terial pleasures.197 Many Tuscan citizens left the city in search of better 
fortunes in response to intertown fighting and social unrest.198 
This hypothesis, while fanciful, highlights why a person’s genes are 
not merely a function of biology. Rather, genetic diversity represents 
choices made by individuals in response to particular cultural and histor-
ical circumstances. Who we choose to marry, how many children we 
choose to have, and where we choose to live are all decisions that influ-
ence the genetic makeup of our future descendents. Gene sequences, 
then, convey information about our cultural heritage. Because exclusio-
nary rights granted by patents on gene sequences generate wealth for pa-
tent holders, cultural heritage is commoditized when patents are granted 
for human gene sequences. Such commoditization benefits the patent 
holder at the expense of the individual when access to an individual’s 
genetic makeup is unfairly restricted. 
The plaintiffs in Molecular Pathology were denied access to infor-
mation about their susceptibility to cancer because the cost of the diag-
nostic test was prohibitively expensive.199 As a result, they were denied 
access to knowledge about the specific mutations they carry. They were 
denied access to mutations shared by family members that resulted from 
a particular cultural trajectory. The plaintiffs were denied access to a part 
of their intangible cultural heritage. In this instance, patents directly con-
flict with personal rights to access information about an individual’s past, 
present, and future. 
B. Protecting Human Gene Sequences 
Human DNA sequences identify two important pieces of informa-
tion. First, sequences give researchers information about an individual’s 
genetic makeup. Patents on gene sequences prevent clinicians from test-
ing for genetic diseases unless they pay the patent holder for use rights. 
Second, DNA sequences represent an individual’s cultural heritage, and 
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patented genes misappropriate rights to that information. Because no log-
ical distinction can be made between the gene sequence as it exists in the 
cell and the sequence after it has been isolated, the DNA sequence can be 
construed as both a product of nature and a piece of intangible cultural 
heritage. Gene-sequence patents should be invalidated because they grant 
exclusionary rights over naturally and culturally derived information. 
In its recent amicus brief agreeing in part with the district court’s 
ruling in Molecular Pathology, the U.S. Department of Justice (DOJ) 
reversed its former stance that isolated gene sequences are patentable 
subject matter.200 The amicus brief stated that “the unique chain of chem-
ical base pairs that induces a human cell to express a BRCA protein is 
not a ‘human-made invention . . . .’”201 While it is true that the gene se-
quence was not invented by the researcher that discovered it, the se-
quence can be conceptualized both as a product of nature and as a prod-
uct of human ingenuity. Dynamic interplay between natural processes 
and human choice created the variation found in the human genome, and 
genes tell the story of our cultural heritage. 
Intangible cultural heritage is protected under multiple international 
declarations and conventions.202 These agreements protect intangible cul-
tural heritage from misappropriation by encouraging member nations to 
respect the value of culturally derived information to its producers, their 
cultural descendents, and humanity.203 Initially, cultural heritage was 
considered a form of personal property.204 Attaching personal property 
rights to cultural heritage, however, is particularly problematic. Afford-
ing group rights to an article of culture creates a static right of ownership 
for a particular group.205 Gene sequences contain mutations that may be 
shared by different groups either because the mutations were inherited or 
because they arose independently. Therefore, it would be impossible to 
tease apart the exact lineage of each individual and assign a property in-
terest for each gene. 
The protective interest over gene sequences is better construed as a 
common duty to protect human sequence data from commercial exploita-
tion and appropriation. Unlike CHPD theory, the conflict of rights does 
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not derive from inherent property rights to the whole genome. Rather, the 
conflict arises because exclusionary rights are granted over small pieces 
of information that either independently or collectively tell a story about 
an individual’s cultural identity. Patent law inappropriately gives the pa-
tent holder the power to restrict or prohibit access to information that is 
both personal and communal.206 
VI. CONCLUSION 
The BRCA litigation has forced the courts to address the gene-
patent debate head on. The case illustrates the harm posed by gene pa-
tents: individuals are denied access to genetic tests because a patent 
holder exercises exclusionary rights over a gene sequence. Patent law is 
designed to promote and create incentives for scientific innovation and to 
disclose important discoveries to the public. In this instance, however, 
patents on human gene sequences are both legally and ethically question-
able, and the USPTO’s current patent policy fails to weigh competing 
interests adequately. By deferring to business interests without critically 
evaluating the subject matter of gene-sequence patents, the USPTO 
grants exclusionary patent rights that directly conflict with access rights 
to intangible cultural heritage. DNA is more than a biological molecule; 
it contains information that uniquely identifies an individual’s cultural 
and evolutionary history. As such, this information should be recognized 
and protected as a form of intangible cultural heritage. 
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